Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance.

Lee I, Zaoutis TE, Fishman NO, Morales KH, Nachamkin I, Lautenbach E.

Am J Infect Control. 2010 Aug;38(6):456-60. doi: 10.1016/j.ajic.2009.12.011. Epub 2010 Apr 3.

PMID:
20371135
2.

Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.

Tumbarello M, Sanguinetti M, Trecarichi EM, La Sorda M, Rossi M, de Carolis E, de Gaetano Donati K, Fadda G, Cauda R, Posteraro B.

J Antimicrob Chemother. 2008 Dec;62(6):1379-85. doi: 10.1093/jac/dkn381. Epub 2008 Sep 8.

PMID:
18782778
3.

Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.

Klevay MJ, Horn DL, Neofytos D, Pfaller MA, Diekema DJ; PATH Alliance..

Diagn Microbiol Infect Dis. 2009 Jun;64(2):152-7. doi: 10.1016/j.diagmicrobio.2009.03.007. Epub 2009 Apr 18.

PMID:
19376667
4.

Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections.

Lee I, Morales KH, Zaoutis TE, Fishman NO, Nachamkin I, Lautenbach E.

Am J Infect Control. 2010 Nov;38(9):740-5. doi: 10.1016/j.ajic.2010.02.016. Epub 2010 Jun 12.

5.

The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.

Magill SS, Swoboda SM, Shields CE, Colantuoni EA, Fothergill AW, Merz WG, Lipsett PA, Hendrix CW.

Ann Surg. 2009 Apr;249(4):657-65. doi: 10.1097/SLA.0b013e31819ed914.

PMID:
19300221
6.

Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.

Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA.

J Clin Microbiol. 2006 May;44(5):1740-3.

7.

Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Lee I, Fishman NO, Zaoutis TE, Morales KH, Weiner MG, Synnestvedt M, Nachamkin I, Lautenbach E.

Arch Intern Med. 2009 Feb 23;169(4):379-83. doi: 10.1001/archinte.169.4.379.

8.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3185-90. doi: 10.1128/JCM.00946-09. Epub 2009 Aug 5.

9.
10.

Risk factors for fluconazole-resistant candidemia.

Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, Cisneros JM, Ortiz-Leyba C.

Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54. doi: 10.1128/AAC.00479-10. Epub 2010 May 24.

11.

Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, Bille J, Chang SC, da Luz Martins M, Duse A, Dzierzanowska D, Ellis D, Finquelievich J, Gould I, Gur D, Hoosen A, Lee K, Mallatova N, Mallie M, Peng NG, Petrikos G, Santiago A, Trupl J, VanDen Abeele AM, Wadula J, Zaidi M; Global Antifungal Surveillance Group..

Diagn Microbiol Infect Dis. 2010 Jun;67(2):162-71. doi: 10.1016/j.diagmicrobio.2010.01.002. Epub 2010 Mar 24.

PMID:
20338711
12.

Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.

Shin JH, Chae MJ, Song JW, Jung SI, Cho D, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW.

J Clin Microbiol. 2007 Aug;45(8):2385-91. Epub 2007 Jun 20.

13.

Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy.

Goswami D, Goswami R, Banerjee U, Dadhwal V, Miglani S, Lattif AA, Kochupillai N.

J Infect. 2006 Feb;52(2):111-7.

PMID:
15908007
14.

In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.

Drago M, Scaltrito MM, Morace G; GISIA-2 Group..

Eur J Clin Microbiol Infect Dis. 2004 Aug;23(8):619-24. Epub 2004 Jul 16.

PMID:
15258831
15.

Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.

Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidemia Study Group..

Antimicrob Agents Chemother. 2012 May;56(5):2518-23. doi: 10.1128/AAC.05947-11. Epub 2012 Feb 6.

16.
17.

Candida glabrata fungaemia in intensive care units.

Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR.

Clin Microbiol Infect. 2008 Feb;14(2):136-40. Epub 2007 Nov 28.

18.

A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.

Wilson AG, Micek ST, Ritchie DJ.

Clin Ther. 2005 Aug;27(8):1228-37.

PMID:
16199247
19.

Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.

Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, Kollef MH.

Crit Care Med. 2007 Apr;35(4):1077-83.

PMID:
17312565
20.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2003 May;41(5):2176-9.

Supplemental Content

Support Center